

***Nancyclotep has obtained €7 million in funding and has partnered with PMB to strengthen its position as a reference center for Vectorized Internal Radiation Therapy in France.***

Nancy (France) – May 29, 2019

Nancyclotep has embarked in a significant investment program to become a reference center for vectorized internal radiation therapy in France. In order to further establish its position, Nancyclotep has partnered with PMB, a subsidiary of the ALCEN group, which manufactures small cyclotrons and automated robotic systems for producing radiopharmaceuticals. Together, the two entities obtained a European funding of €7.2 million. This global project, totaling more than €15 M, will allow the implementation of a technical platform including a mini-cyclotron, an automatic robotic system to produce radiopharmaceuticals, a conventional radiopharmaceutical production unit, a radiochemistry laboratory and a preclinical platform. In parallel, a 14-bed treatment unit, dedicated to vectorized internal radiation therapy with both alpha- and beta-emitting radionuclides, was created at the Nancy University Hospital Center.

Nancyclotep's Administrator, Prof. Gilles Karcher, proudly declares « Work has begun. The technical platform and the care unit will be operational in the first quarter of 2020. Nancyclotep is already a clinical trial operator with local access to Zirconium 89, Gallium 68 and Copper 64 sources; with this investment we wish to meet the growing needs of pharmaceuticals and become a major player in the field of radiotheranostics ».

Nancyclotep's management team will be attending the SNMMI Nuclear Medicine Congress in Anaheim, June 22-25, 2019, to meet their future partners.

**About Nancyclotep**

Founded in 2007, Nancyclotep develops and offers solutions ranging from R&D to clinical studies and production, enabling to meet the needs for the transfer of radiopharmaceuticals to the clinical setting. Nancyclotep is a public-private economic interest group, based at the Nancy University Hospital (France), which employs 18 people.

Nancyclotep features state-of-the-art facilities including a radiochemistry and radiopharmacy laboratory, a preclinical studies platform, an industrial production laboratory, 3 PET-scans, an e-learning laboratory offering innovative solutions and a hospital environment enabling immediate access to medical skills and patients for clinically useful technological applications. For more information, visit: [www.nancyclotep.inist.fr/](http://www.nancyclotep.inist.fr/)

---

**Nancyclotep Contact**

Prof. Gilles Karcher  
Chairman and CEO  
[g.karcher@chu-nancy.fr](mailto:g.karcher@chu-nancy.fr)

Dr. Marjorie Fougère  
General Manager  
[m.fougere@nancyclotep.com](mailto:m.fougere@nancyclotep.com)